Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced the appointments of David Becker as Chief Financial Officer, Charles (“Chuck”) Hrushka as Vice President of Sales & Marketing, and Leslie White as Director of Regulatory Affairs & Quality Assurance. Pernix expects the additions of Messrs. Becker, Hrushka and White to its management team will enhance the Company’s ability to support its growth strategy in pediatrics as well as pursue opportunities in additional therapeutic areas.

David Becker has more than 10 years of experience in the healthcare industry, which includes an extensive background in the cough, cold and allergy markets. From 2000 to 2007, Mr. Becker served as Executive Vice President, Chief Financial and Administrative Officer & Treasurer of Adams Respiratory Therapeutics, Inc., a specialty pharmaceutical company with a large presence in the cough, cold and allergy market prior to its acquisition by Reckitt Benckiser Group plc. Mr. Becker served as Executive Vice President & Chief Financial Officer of MiddleBrook Pharmaceuticals, Inc. Mr. Becker also gained experience in mergers & acquisitions while at Ernst & Young LLP. Throughout his career, Mr. Becker has built a strong track record of providing strategic direction and corporate growth, completing numerous financings and acquisitions. He has played a key role in growing branded products, such as Mucinex, and acquiring brands, including Delsym. He received a Bachelor of Science in Accounting from the University of Southern Mississippi and is a certified public accountant in the state of California.

Chuck Hrushka has over 25 years of global sales and marketing experience in the pharmaceutical and biotechnology industries. As Vice President of Sales & Marketing, he will be responsible for managing the development and execution of Pernix’s marketing function and sales plan, and will report to Mr. Collins. Prior to joining Pernix, he served as Vice President of Marketing of Shionogi Pharma, Inc. (formerly Sciele Pharma, Inc.), a global specialty pharmaceutical company that develops and commercializes products in the areas of pediatrics, women’s health and cardiovascular. He also has experience in gastroenterology when he served as Vice President of Marketing for Sucampo Pharmaceuticals, Inc. Mr. Hrushka has also held senior sales and marketing positions at Burren Pharmaceuticals, Schebo Biotech USA, Axcan Pharma, and Solvay Pharmaceuticals. He earned an Masters in Business Administration from Georgia State University and a Bachelor of Science in Biology from Lynchburg College.

If you liked this article you might like

5 Stocks Under $10 Set to Soar

These 5 Stocks Are Breaking Out

5 Stocks Under $10 Set to Soar

Today's Weak On High Volume Stock: Pernix Therapeutics Holdings (PTX)

Pernix Therapeutics Holdings (PTX) Highlighted As Weak On High Volume